Characterization of liver specific promoters in a foamy viral vector pMD09

被引:4
|
作者
Singh, A. K. [1 ]
Weber, C. [2 ]
Varshney, A. [1 ]
Gupta, S. [1 ]
Kazim, S. N. [3 ]
Sanal, M. G. [1 ]
Rethwilm, A. [2 ]
Sarin, S. K. [4 ]
机构
[1] Inst Liver & Biliary Sci, Dept Mol & Cellular Med, New Delhi, India
[2] Univ Wurzburg, Inst Virol & Immunbiol, Versbacher Str 7, D-97078 Wurzburg, Germany
[3] Jamia Millia Islamia, Hepatitis Res Lab, Ctr Interdisciplinary Res Basic Sci, New Delhi, India
[4] Inst Liver & Biliary Sci, Dept Hepatol, New Delhi, India
关键词
foamy virus; gene therapy; liver; albumin; transthyretin promoter; HBV promoter; GENE-THERAPY; VIRUS VECTORS;
D O I
10.4149/av_2019_207
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Foamy viruses (FVs) or spumaviruses are retroviruses that are explored as vectors for gene therapy. The good feature of foamy viruses is its broad tropism; however, their infections result in non-targeted gene expression. Here, we attempted to design the liver targeted viral gene delivery by employing liver specific gene promoters like albumin (ALB), transthyretin (TTR) and hepatitis B virus (HBV) promoters. We compared the relative gene expression of liver specific promoters versus the U3 promoter in liver cell line (HepG2) and non-liver cell lines: human fibrosarcoma cell line (HT1080), baby hamster kidney cell line (BHK), human embryonic kidney cell line (HEK 293T) and cervical cancer cell line (HeLa). We have found that the promoter exchange didn't affect viral assembly. The ability to drive gene expression was best with TTR promoter which was followed by HBV and ALB promoter. The use of TTR, HBV and ALB promoters are helpful in achieving liver specific gene expression.
引用
收藏
页码:162 / +
页数:10
相关论文
共 6 条
  • [1] CHARACTERIZATION OF LIVER SPECIFIC PROMOTER IN FOAMY VIRAL VECTOR FOR LIVER SPECIFIC GENE THERAPY
    Singh, Avishek K.
    Kazim, Syed N.
    Rethwilm, Axel
    Sarin, Shiv K.
    HEPATOLOGY, 2011, 54 : 791A - 791A
  • [2] COMPARATIVE STUDY OF CHIMERIC LIVER-SPECIFIC PROMOTER EXPRESSION FROM A NON-VIRAL VECTOR FOR HEPATIC GENE THERAPY
    Viecelli, H. M.
    Wong, S. P.
    Harbottle, R. P.
    Petrus, I
    Chuah, M.
    VandenDriessche, T.
    Thony, B.
    JOURNAL OF INHERITED METABOLIC DISEASE, 2010, 33 : S166 - S166
  • [3] Potent knockdown of viral replication following lentiviral vector-mediated delivery of liver-specific micro RNA mimics targeting HBV
    Ivacik, Dejana
    Ely, Abdullah
    Arbuthnot, Patrick
    Ferry, Nicolas
    HUMAN GENE THERAPY, 2012, 23 (10) : A118 - A118
  • [4] ANGIOTENSIN-CONVERTING ENZYME 2 GENE THERAPY USING A HIGH EFFICIENCY AND LIVER-SPECIFIC ADENO-ASSOCIATED VIRAL VECTOR ATTENUATES LIVER FIBROSIS IN MICE
    Mak, Kai Yan
    Chin, Ruth
    Cunningham, Sharon C.
    Habib, Miriam
    Torresi, Joseph
    Sharland, Alexandra F.
    Alexander, Ian E.
    Angus, Peter W.
    Herath, Chandana B.
    JOURNAL OF GENE MEDICINE, 2015, 17 (8-9): : 205 - 206
  • [5] ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) GENE THERAPY USING A HIGH EFFICIENCY AND LIVER-SPECIFIC ADENO-ASSOCIATED VIRAL VECTOR ATTENUATES EXPERIMENTAL LIVER FIBROSIS IN MICE
    Mak, K. Y.
    Chin, R.
    Torresi, J.
    Cunningham, S. C.
    Alexander, I. E.
    Angus, P. W.
    Herath, C. B.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S268 - S269
  • [6] Angiotensin converting enzyme 2 (ACE2) gene therapy using a high efficiency and liver-specific adeno-associated viral vector attenuates experimental liver fibrosis in mice
    Mak, K. Y.
    Chin, R.
    Torresi, J.
    Cunningham, S.
    Alexander, I.
    Angus, P. W.
    Herath, C. B.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2014, 29 : 4 - 4